August 6, 2014 / 11:30 AM / 3 years ago

Roche says Avastin approved in EU for type of ovarian cancer

ZURICH (Reuters) - Roche said on Wednesday that European regulators approved its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy.

Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was the Basel-based drugmaker’s biggest seller last year with sales of 6.25 billion Swiss francs ($6.9 billion).

The move endorses a favorable recommendation last month from the European Medicine Agency’s Committee for Medicinal Products for Human Use(CHMP), which are normally followed by the European Commission.

($1 = 0.9096 Swiss franc)

Reporting By Katharina Bart; Editing by Maria Sheahan

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below